<?xml version="1.0" encoding="UTF-8"?>
<Progress_Report_Checklist
><Grant_Information
><RFA_Number
>06-01</RFA_Number
><Grant_Number
>RS1-00210-1</Grant_Number
><Reporting_Period_Start
>8/1/2008</Reporting_Period_Start
><Reporting_Period_End
>7/31/2009</Reporting_Period_End
><Institution_Name
>The J. David Gladstone Institutes</Institution_Name
><Primary_Investigator
><Prefix
/><First_Name
>Warner</First_Name
><Middle_Name
/><Last_Name
>Greene</Last_Name
><Suffix
/><Degree
/><Institution
/><Title
/><Department
/><Email
/><Telephone_Number
/><Extension
/><Fax_Number
/></Primary_Investigator
></Grant_Information
><Reviewer_Information
><Grants_Manager
><Prefix
/><First_Name
/><Middle_Name
/><Last_Name
/><Suffix
/><Degree
/><Institution
/><Title
/><Department
/><Email
>alewis</Email
><Telephone_Number
/><Extension
/><Fax_Number
/></Grants_Manager
><Science_Officer
><Prefix
/><First_Name
/><Middle_Name
/><Last_Name
/><Suffix
/><Degree
/><Institution
/><Title
/><Department
/><Email
>ugrieshammer</Email
><Telephone_Number
/><Extension
/><Fax_Number
/></Science_Officer
></Reviewer_Information
><Reviews
><Budget_Review
><IsRequired
/><Grant_Manager_Notes
>Grantee reports $7,327 unspent funds at end of total award period.  Final amount to be confirmed via financial report.</Grant_Manager_Notes
><Science_Officer_Notes
/><Grant_Manager_Approval
>1</Grant_Manager_Approval
><Science_Officer_Approval
>1</Science_Officer_Approval
><IsComplete
/></Budget_Review
><California_Supplier_Review
><IsRequired
/><Grant_Manager_Notes
>Grantee reports 54% of purchases from CA suppliers.</Grant_Manager_Notes
><Science_Officer_Notes
/><Grant_Manager_Approval
>1</Grant_Manager_Approval
><Science_Officer_Approval
/><IsComplete
/></California_Supplier_Review
><Key_Personnel_Review
><IsRequired
/><Grant_Manager_Notes
/><Science_Officer_Notes
>175% hands on reported, this is up from 92% in year 1, and closer to 250% originally proposed</Science_Officer_Notes
><Grant_Manager_Approval
/><Science_Officer_Approval
>1</Science_Officer_Approval
><IsComplete
/></Key_Personnel_Review
><IACUC_Assurances_Review
><IsRequired
>0</IsRequired
><Grant_Manager_Notes
/><Science_Officer_Notes
/><Grant_Manager_Approval
>0</Grant_Manager_Approval
><Science_Officer_Approval
>0</Science_Officer_Approval
><IsComplete
/></IACUC_Assurances_Review
><IRB_Assurances_Review
><IsRequired
>0</IsRequired
><Grant_Manager_Notes
/><Science_Officer_Notes
/><Grant_Manager_Approval
>0</Grant_Manager_Approval
><Science_Officer_Approval
>0</Science_Officer_Approval
><IsComplete
/></IRB_Assurances_Review
><SCRO_Assurances_Review
><IsRequired
>1</IsRequired
><Grant_Manager_Notes
>SCRO approval # G7396-29609-04 valid from 5/12/09 - 5/11/2010.  No gaps in coverage from previous approval.</Grant_Manager_Notes
><Science_Officer_Notes
>agree with Amy</Science_Officer_Notes
><Grant_Manager_Approval
>1</Grant_Manager_Approval
><Science_Officer_Approval
>1</Science_Officer_Approval
><IsComplete
/></SCRO_Assurances_Review
><Publication_Reporting_Review
><IsRequired
>0</IsRequired
><Grant_Manager_Notes
/><Science_Officer_Notes
/><Grant_Manager_Approval
>0</Grant_Manager_Approval
><Science_Officer_Approval
>0</Science_Officer_Approval
><IsComplete
/></Publication_Reporting_Review
><Invention_Licensing_Review
><IsRequired
>0</IsRequired
><Grant_Manager_Notes
/><Science_Officer_Notes
/><Grant_Manager_Approval
>0</Grant_Manager_Approval
><Science_Officer_Approval
>0</Science_Officer_Approval
><IsComplete
/></Invention_Licensing_Review
><PI_Effort_Review
><IsRequired
>0</IsRequired
><Grant_Manager_Notes
>None.</Grant_Manager_Notes
><Science_Officer_Notes
>3 of the listed grants started after the end of the SEED grant (7-31-09), so in effect, during year 2, total effort was only at 65%</Science_Officer_Notes
><Grant_Manager_Approval
/><Science_Officer_Approval
>1</Science_Officer_Approval
><IsComplete
/><Total_Current_Effort
>100</Total_Current_Effort
><CIRM_Award_Effort
>5</CIRM_Award_Effort
></PI_Effort_Review
></Reviews
><Award_Conditions
><Conditions_Exist
>0</Conditions_Exist
><Conditions_Met
><Conditions_Met
/><Grants_Manager_Notes
/><Grants_Manager_Approval
>0</Grants_Manager_Approval
><Science_Officer_Notes
/><Science_Officer_Approval
>0</Science_Officer_Approval
></Conditions_Met
><New_Conditions
><New_Conditions
>0</New_Conditions
><Grants_Manager_Notes
/><Grants_Manager_Approval
>0</Grants_Manager_Approval
><Science_Officer_Notes
/><Science_Officer_Approval
>0</Science_Officer_Approval
></New_Conditions
></Award_Conditions
><Prior_Approval
><IsRequired
>1</IsRequired
><Grant_Manager_Notes
>Budget changes require PAR.  See Amendment 1.</Grant_Manager_Notes
><Science_Officer_Notes
>PAR approved</Science_Officer_Notes
><Grant_Manager_Approval
>1</Grant_Manager_Approval
><Science_Officer_Approval
>1</Science_Officer_Approval
><IsComplete
/></Prior_Approval
><OtherIssues
/><Evaluation
><Overall_Rating
>Satisfactory</Overall_Rating
><Translational_Status
>No substantial change, incremental, or N/A</Translational_Status
><Executive_Summary
>In Year 2 of this project, progress toward Aim 1 consisted of continuing experiments started in year 1, providing a more comprehensive analysis with the inclusion of hESC line H13, and 2 hiPSC lines in addition to H9. The overall conclusion is that pluripotent stem cell lines express 5/6 APOBEC3 genes, and display active Line1 retroelement expression. Minor data are provided on the expression of other retroelements. Further, the PI showed that Alu mRNA is sequestered in HMM A3G complexes in hESC, suggesting that this may interrupt the retrotransposition cycle, thereby protecting hESC from retrotransposition. The goal of Aim 1 has been partially achieved by the conclusion of this grant. &#xD;&#xD;Toward Aim2, to assess if specific A3 proteins actively oppose LINE1 or Alu retrotransposition in hESC, the PI improved the LINE1 retrotransposition assay, using an eGFP-based construct that allows analysis of retrotransposition events by FACS. The PI shows a reproducible, low frequency retrotransposition activity in H9, H13, and iPSC, whereas HeLa cells display a 10x higher level. Using this assay system, the PI further shows that knock down of A3B but not other A3 genes leads to an increase in LINE1 retrotransposition, providing an answer to the question posed for this aim. No data on Alu retrotransposition were reported.&#xD;&#xD;Minimal progress toward Aim 3 was reported in year 2, as knock down of A3 genes in hESC did not result in changes to Oct4 or TRA1-81 staining, ie pluripotency seems unaffected, and A3 gene knock down does not affect the ability of hESC to form embryoid bodies.&#xD;&#xD;Overall, although the aims of this grant were not achieved in their entirety, significant progress has been made toward answering some of the posed questions. However, the arguably most important question, whether increased retrotransposition increases the frequency of malignant transformation of hESC, has not been addressed.&#xD;</Executive_Summary
></Evaluation
><Strategic_Outcome
><Five_Year_Goal_1
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Five_Year_Goal_1
><Five_Year_Goal_2
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Five_Year_Goal_2
><Five_Year_Goal_3
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Five_Year_Goal_3
><Five_Year_Goal_4
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Five_Year_Goal_4
><Five_Year_Goal_5
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Five_Year_Goal_5
><Five_Year_Goal_6
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Five_Year_Goal_6
><Five_Year_Goal_8
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Five_Year_Goal_8
><Ten_Year_Goal_1
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Ten_Year_Goal_1
><Ten_Year_Goal_2
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Ten_Year_Goal_2
><Ten_Year_Goal_5
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Ten_Year_Goal_5
><Ten_Year_Goal_7
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Ten_Year_Goal_7
><Ten_Year_Goal_8
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Ten_Year_Goal_8
><Ten_Year_Goal_9a
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Ten_Year_Goal_9a
><Ten_Year_Goal_9b
><IsApplicable
>1</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
>analysis of retrotransposition was begun, interesting results were reported in progress report, but whether the observed retrotransposition affects malignancy of hESC, although a goal, was not analyzed.</Outcomes
><Impact_Factor
>2</Impact_Factor
></Ten_Year_Goal_9b
><Ten_Year_Goal_10
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Ten_Year_Goal_10
><OtherOutcomes
><IsApplicable
>1</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
>development of effective LINE1 retrotransposition assay that now can be used for detailed analyses in pluripotent stem cells</Outcomes
><Impact_Factor
>2</Impact_Factor
></OtherOutcomes
></Strategic_Outcome
><IsComplete
/></Progress_Report_Checklist
>